108 related articles for article (PubMed ID: 28691553)
1. The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.
Kiss KP; Varga G; Mikala G; Balassa K; Bors A; Kovy P; Meggyesi N; Kozma A; Csacsovszki O; Remenyi P; Valyi-Nagy I; Tordai A; Masszi T; Andrikovics H
Leuk Lymphoma; 2018 Mar; 59(3):710-716. PubMed ID: 28691553
[TBL] [Abstract][Full Text] [Related]
2. Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Varga G; Mikala G; Kiss KP; Kosóczki É; Szabó E; Meggyesi N; Balassa K; Kövy P; Tegze B; Szombath G; Tordai A; Andrikovics H; Homolya L; Masszi T
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):734-742. PubMed ID: 28733196
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
Ziv E; Dean E; Hu D; Martino A; Serie D; Curtin K; Campa D; Aftab B; Bracci P; Buda G; Zhao Y; Caswell-Jin J; Diasio R; Dumontet C; Dudziński M; Fejerman L; Greenberg A; Huntsman S; Jamroziak K; Jurczyszyn A; Kumar S; Atanackovic D; Glenn M; Cannon-Albright LA; Jones B; Lee A; Marques H; Martin T; Martinez-Lopez J; Rajkumar V; Sainz J; Vangsted AJ; Wątek M; Wolf J; Slager S; Camp NJ; Canzian F; Vachon C
Nat Commun; 2015 Jul; 6():7539. PubMed ID: 26198393
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
6. Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma.
Choi YW; Park JS; Han JH; Kim JH; Ahn MS; Lee HW; Kang SY; Choi JH; Jeong SH
Leuk Lymphoma; 2018 Nov; 59(11):2670-2678. PubMed ID: 29582699
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
[TBL] [Abstract][Full Text] [Related]
8. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.
Zhou X; Wang J; Xia J; Cheng F; Mao J; Zhu J; Guo H
Cancer Biomark; 2018; 22(1):43-48. PubMed ID: 29562497
[TBL] [Abstract][Full Text] [Related]
12. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
13. High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS.
Breczko W; Lemancewicz D; Dzięcioł J; Kłoczko J; Bołkun Ł
Adv Med Sci; 2021 Mar; 66(1):21-27. PubMed ID: 33246214
[TBL] [Abstract][Full Text] [Related]
14. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
16. Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Sood N; Hamide A; Dubashi B; Nisha Y; Mathaiyan J; Munirajan AK; Ganesn P; Kayal S
Asian Pac J Cancer Prev; 2024 Mar; 25(3):829-837. PubMed ID: 38546066
[TBL] [Abstract][Full Text] [Related]
17. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
18. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
[TBL] [Abstract][Full Text] [Related]
19. TP53 polymorphism in plasma cell myeloma.
Zmorzynski SA; Korszen-Pilecka I; Wojcierowska-Litwin M; Kwiatkowska-Drabik B; Luterek M; Chocholska S; Koczkodaj D; Popek S; Michalak-Wojnowska M; Swiderska-Kolacz G; Januszewska J; Surowiec I; Tomczak W; Hus M; Dmoszynska A; Pasiarski M; Poniewierska-Jasak K; Cieplinska K; Jankowska-Lecka O; Filip AA
Folia Histochem Cytobiol; 2017; 55(4):203-211. PubMed ID: 29333597
[TBL] [Abstract][Full Text] [Related]
20.
Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
